

# **The Handbook of Medicinal Chemistry**

## **Principles and Practice**

### **2nd Edition**

**Edited by**

**Simon E. Ward**

*Cardiff University, UK*

*Email: WardS10@cardiff.ac.uk*

and

**Andrew M. Davis**

*AstraZeneca, Sweden*

*Email: andy.davis@astrazeneca.com*

ROYAL SOCIETY  
OF **CHEMISTRY**

# Contents

<b>1</b>	<b>Physicochemical Properties</b>	<b>1</b>
	<i>Andrew M. Davis and Paul D. Leeson</i>	
1.1	Introduction	1
1.2	Physicochemical Properties	1
1.3	Lipophilicity	2
1.3.1	Measuring Log <i>P</i> and Log <i>D</i>	4
1.3.2	Zwitterions	7
1.3.3	Other Solvent Systems	8
1.3.4	Membrane–Water Partition Coefficients	9
1.3.5	Chromatographic Log <i>D</i> Measurement	9
1.3.6	Calculating Log <i>P</i> and Log <i>D</i> <sub>7.4</sub>	10
1.4	Ionisation Constants	11
1.4.1	Measuring Ionisation Constants	12
1.4.2	Calculating Ionisation Constants	12
1.4.3	Manipulating p <i>K</i> <sub>a</sub> in Medicinal Chemistry Strategy	14
1.5	Hydrogen Bonding	15
1.5.1	Polar Surface Area	20
1.5.2	Quantifying the Contribution of a Hydrogen Bond	20
1.6	Solubility	22
1.6.1	Measurement of Solubility	23
1.6.2	Calculating Solubility	24
1.7	The Rule of Five	24
1.7.1	Beyond the Rule of Five	26
1.8	Ligand Efficiency Metrics	28
1.9	Compound Quality and Drug-likeness	32
1.10	Conclusions	34
1.11	Hints and Tips	35
	Key References	35
	References	36

<b>2</b>	<b>Synthesis in Medicinal Chemistry</b>	<b>40</b>
	<i>Allan M. Jordan and Robert J. Young</i>	
2.1	The State of the Art – Where are We, and How did We Get Here?	40
2.1.1	The Evolving Landscape of Synthetic Medicinal Chemistry – Changes in Discovery Practices	41
2.1.2	Why Do We Use the Reactions We Use?	43
2.1.3	We are Where we are – but Does it Matter?	47
2.2	How to Improve Molecules Through Synthesis	48
2.2.1	Some Historic Examples where Synthesis Enabled Discovery	48
2.2.2	Four Strategies to Improve Molecules: Methylation, Hydroxylation, Fluorination and Heterocycles	51
2.2.3	Better Late-stage Functionalisation	53
2.2.4	Biotransformations	54
2.2.5	Water-based Chemistry	59
2.2.6	Mimicking Nature	60
2.2.7	Isosteres	67
2.2.8	Fragment-Based Drug Discovery (FBDD)	68
2.2.9	Avoiding Nuisance Compounds, PAINS and Potentially Reactive Species	73
2.3	Improving the Efficiency of Synthetic Medicinal Chemistry	74
2.3.1	AI/Machine Learning in Synthesis Planning	76
2.3.2	Automation and Linking to Reaction Planning	78
2.3.3	Synthetic Techniques and Technologies: Flow Chemistry	79
2.3.4	Purification Technologies and Compound Handling	81
2.4	Case Studies	83
2.4.1	AMG-176	83
2.4.2	E7130, C52-Halichondrin-B-amine	84
2.5	The Future? New Modalities and Synthetic Impact	86
	References	88
<b>3</b>	<b>Useful Computational Chemistry Tools for Medicinal Chemistry</b>	<b>94</b>
	<i>Darren V. S. Green and Colin M. Edge</i>	
3.1	Physics-based vs. Empirical Models	94
3.2	Molecular Mechanics and Molecular Orbital Theory	95
3.2.1	Quantum Mechanics	97
3.2.2	Molecular Mechanics	101
3.2.3	Electronic Distribution and Electrostatic Isopotentials	103
3.2.4	3-Dimensional Molecular Similarity	104
3.2.5	Energy Minimisation	105
3.3	Molecular Simulation and Dynamics	105
3.4	Modelling Solvation	109

3.5 Conformations, Conformational Energy and Drug Design	112
3.6 Quantifying Molecular Interactions from Experimental Data	115
3.7 Docking and Scoring Functions	116
3.8 Cheminformatics	120
3.9 Examples of Impactful Computational Chemistry on Drug Design	126
3.10 Hints and Tips	130
References	132

## 4 Structure-based Design for Medicinal Chemists 137

*Jeff Blaney and Andrew M. Davis*

4.1 Introduction	137
4.2 History	138
4.3 Protein Structures for Structure-based Design	139
4.3.1 Experimentally Determined Structures	139
4.3.2 Limitations of the Use of X-ray Crystal and Cryo-EM Structures	140
4.3.3 Predicting Protein Structures: AlphaFold and RoseTTAFold	141
4.4 Theory and Practice of Structure-based Design	142
4.4.1 Visualizing Shape Complementarity	142
4.4.2 What Drives Binding?	144
4.4.3 Favorable and Unfavorable Waters and Water Networks	145
4.4.4 Protein Flexibility	147
4.4.5 Enthalpy–Entropy Compensation	148
4.4.6 Electrostatics	149
4.4.7 Small Molecules Bind in Their Lowest Energy, Preferred Conformations	150
4.4.8 Preferred and Competitive Protein–Ligand Interactions	152
4.5 Ligand-induced Conformational Change	160
4.5.1 Hypothesis-based Design	165
4.5.2 Predicting Affinity: Free Energy Perturbation	168
4.5.3 Test the Quality of a Design with Ligand Strain Energy, MD, and Docking	170
4.5.4 Large-scale Virtual Screening	171
4.5.5 Visual Docking Pose Assessment and Human Expertise	171
4.5.6 Covalent Inhibitor Design	172
4.6 Future Directions	173
4.6.1 DNA Encoded Libraries	174
4.6.2 DEL and Machine Learning	174
4.6.3 PROTAC Degradors and Molecular Glues	175
4.6.4 Cryo-EM	176
4.6.5 Machine Learning (ML)	179
4.7 Summary	179
4.8 Hints and Tips	180
Key References	181
References	182

## 5 Fragment-based Ligand Discovery (FBLD) 188

Roderick E. Hubbard

5.1 Introduction	188
5.2 The General Features of FBLD	189
5.3 Fragment Library	190
5.4 Fragment Screening Approaches	194
5.4.1 Protein-observed NMR	194
5.4.2 Ligand-observed NMR	195
5.4.3 Technologies that Sense Binding to Labelled Protein Through Change in Optical Properties	197
5.4.4 Thermal Shift Analysis (TSA) or Differential Scanning Fluorimetry	199
5.4.5 Biochemical Assay	199
5.4.6 Crystallography	200
5.4.7 Mass Spectrometry	201
5.4.8 Isothermal Titration Calorimetry (ITC)	201
5.4.9 Virtual Screening	202
5.4.10 Other Ideas and Approaches	202
5.4.11 Validating Fragment Hits – Comparing Methods	202
5.5 Fragment Hit Rates	203
5.5.1 Hits vs. Non-hits	203
5.5.2 Hits for Different Types of Target	203
5.5.3 Membrane-bound Proteins	203
5.6 Fragments for Chemical Biology – Target and Mechanism Assessment and Discovery	204
5.7 Determining Structures of Fragments Bound	205
5.8 The Evolution of the Ideas and Methods – a Historical Perspective	206
5.8.1 Some Early Ideas	206
5.8.2 The Emergence of <i>De Novo</i> Structure-based Design	206
5.8.3 The Emergence of Fragment-based Discovery	207
5.8.4 What's in a Name?	209
5.8.5 Some Important Underpinning Concepts	209
5.9 Fragment Evolution	210
5.10 Fragments and Chemical Space	210
5.11 Concluding Remarks	211
5.12 Hints and Tips	212
Key References	213
Acknowledgements	213
References	223

## 6 Machine Learning in Drug Design 231

Ola Engkvist, Lewis H. Mervin, Hongming Chen and Ting Ran

6.1 Introduction	231
6.2 Development of Deep Generative Models for Molecular Structure Generation	232
6.2.1 The Emergence of Deep Generative Models	232

6.2.2	SMILES-based Generative Models	233
6.2.3	Graph-based Generative Models	236
6.3	Advances in Deep Learning for ADMET Prediction	237
6.3.1	Prediction of ADMET Properties	237
6.3.2	Applications of Deep Learning in ADMET Prediction	239
6.3.3	Challenges and Opportunities in ADME Modeling	241
6.4	<i>In Silico</i> Protein Target Deconvolution	242
6.4.1	Structure- and Ligand-based Approaches Toward Protein–Ligand Prediction	242
6.4.2	Ligand-based Approaches	243
6.4.3	Extensions to <i>In Silico</i> Target Deconvolution Methods	245
6.4.4	Limitations and Future Concerns for Target Prediction Methods	246
6.5	Synthesis Prediction with Machine Learning	248
6.5.1	Chemical Reaction Data	248
6.5.2	Forward Synthesis Prediction	249
6.5.3	Synthetic Route Prediction	251
6.6	Conclusions	252
6.7	Hints and Tips	253
	Key References	253
	References	254

## 7 Drug Metabolism 265

*R. Lock, P. J. H. Webborn, C. W. Vose and R. M. J. Ings*

7.1	Introduction	265
7.2	Drug Metabolism Pathways	266
7.3	The Key Role of Cytochrome P450 Enzymes	268
7.4	What Are the Key Organs that Metabolise Drugs?	271
7.5	Relationship Between Chemical Structure and Rate of CYP Metabolism	271
7.6	How is Drug Metabolism Studied?	273
7.7	Metabolites in Assessing Drug Safety and Efficacy	275
7.7.1	The Industry Perspective	275
7.7.2	Guidance on Safety Testing of Metabolites	276
7.7.3	Reactive Metabolites	278
7.8	What Factors Influence the Metabolism of Drugs?	280
7.8.1	Dose Level	280
7.8.2	Route of Administration	281
7.8.3	Species Difference in Metabolism	281
7.8.4	Gender-related Differences	283
7.8.5	Age	283
7.8.6	Disease	284
7.8.7	Genetics	284
7.9	Metabolism-based Drug–Drug Interactions	285
7.10	How Transporter Proteins Affect Drug Metabolism	291
7.11	Summary	293
7.12	Drug Metabolism Hints and Tips	294
7.13	Recommended Reading	295
	References	296

## **8 ADME Optimization in Drug Discovery** **298**

*Dermot F. McGinnity and Ken Grime*

8.1	Introduction	298
8.1.1	Absorption	299
8.1.2	Distribution	300
8.1.3	Metabolism	301
8.1.4	Excretion	301
8.2	Optimization and Prediction of Key Human Pharmacokinetic Parameters in Drug Discovery	302
8.2.1	Oral Absorption	303
8.2.2	Volume of Distribution	305
8.2.3	Distribution into Central Nervous System	308
8.2.4	Human Clearance	309
8.3	ADME Considerations for PROTACs	314
8.4	Inhaled, Topical and Intravenous Routes of Administration	315
8.5	Hints and Tips	317
8.6	Summary	318
	References	319

## **9 Molecular Biology for Medicinal Chemists** **324**

*N. M. Ahmad, E. Bush, B. Nancolas, N. Macabuag and P. I. Racz*

9.1	A Brief History of Molecular Biology	324
9.2	Sequencing	328
9.2.1	History of Sequencing	328
9.2.2	Sanger Sequencing	329
9.2.3	Next-generation Sequencing	330
9.2.4	RNA Sequencing	332
9.2.5	Third-generation DNA Sequencing	332
9.3	Gene-editing Methods	334
9.3.1	Zinc Finger Nucleases (ZFNs)	335
9.3.2	Transcription Activator-like Effector Nucleases (TALENs)	335
9.3.3	CRISPR	336
9.3.4	Gene Expression Modulation by RNA Interference (RNAi)	338
9.4	Model Systems	340
9.4.1	Cellular Systems	340
9.4.2	Immortalised Cells	342
9.4.3	Primary Cells	342
9.4.4	Stem Cells	343
9.5	Gene Expression Studies and Their Application	345
9.5.1	Application of PCR	345
9.5.2	Studying Gene Expression by Quantitative Reverse Transcription PCR (qRT-PCR)	346

9.5.3 Digital PCR	348
9.5.4 Reporter Cell Lines	348
9.6 Proteomics in Drug Discovery	350
9.6.1 Protein Microarrays	350
9.6.2 Kinase Profiling	351
9.6.3 Label-free Proteome Profiling	352
9.7 Hints and Tips	353
References	354

## 10 Assays 359

*Barbara Saxty and Peter J. Coombs*

10.1 Assay Detection Technologies	359
10.1.1 Absorbance	359
10.1.2 Fluorescence	360
10.1.3 Luminescence	361
10.1.4 Antibody-based Assays	362
10.1.5 Mass Spectrometry	364
10.1.6 Surface Plasmon Resonance	366
10.1.7 Microscale Thermophoresis (MST)	366
10.1.8 Protein Thermal Shift and CETSA	367
10.1.9 Cell Imaging	367
10.2 Assay Design	369
10.2.1 Biophysical Assays	371
10.2.2 Enzyme Assays	375
10.2.3 Ion Channel Assays	378
10.2.4 GPCR Assays	380
10.2.5 Cell Reporter Gene	382
10.2.6 Cell Phenotypic Assays	383
10.3 Building the Cascade	386
10.3.1 Primary Assay	386
10.3.2 Target Engagement	389
10.3.3 Mode of Action	390
10.4 The Cascade in Practise	392
10.4.1 Data Analysis	392
10.4.2 Biophysical Assay Data Analysis	394
10.4.3 Robustness Analysis and Data Comparison	395
10.4.4 When Assays Fail	395
10.4.5 The SAR Doesn't Track Across Assays in the Cascade	396
10.5 Hints and Tips	397
10.5.1 Assay Design Fundamental Questions	397
10.5.2 Assay Troubleshooting	398
10.5.3 What Can You Do When Your Data Looks Odd?	398
Key References	399
References	399



<b>11</b>	<b><i>In Vitro</i> Biology: Measuring Pharmacological Activity that Will Translate to Clinical Efficacy</b>	<b>402</b>
	<i>Iain G. Dougall, Rachel L. Grimley and Per Erik Strömstedt</i>	
11.1	Introduction: Importance of Detailed Mechanistic Understanding	402
11.2	A Desire to Work With More Physiologically Relevant Systems	403
11.2.1	Target Integrity	404
11.2.2	Complex Binding Partners and Cofactors	405
11.2.3	Binding Interactions and Catalytic Mechanisms	405
11.3	Pharmacological Profiling	406
11.3.1	The Challenge with IC <sub>50</sub>	407
11.3.2	Mechanism of Enzyme Inhibition	408
11.3.3	Slow-binding and Tight-binding Enzyme Inhibition	410
11.4	Translating Through to Dosing: Target Occupancy	415
11.5	Introduction: Receptors	415
11.5.1	Agonist Concentration-effect Curves	417
11.5.2	Full Agonists, Partial Agonists and Inverse Agonists	418
11.5.3	Optimising Agonists	421
11.5.4	Antagonists	423
11.6	Conclusions	431
11.7	Hints and Tips	431
	Key References	432
	Glossary	432
	References	434
<b>12</b>	<b>Animal Models: Practical Use and Considerations</b>	<b>437</b>
	<i>L. A. Lione, M. Lanigan and A. Fisher</i>	
12.1	Introduction	437
12.2	Where Do Animal Models Fit into the Process of Drug Discovery and Development?	440
12.3	Type of Animal Studies Required in Drug Discovery and Development (see Figure 12.5)	444
12.3.1	<i>In Vivo</i> PK Screening	444
12.3.2	<i>In Vivo</i> PD Screening	445
12.3.3	Disease/Mechanism Models	446
12.3.4	Toxicology Models	449
12.4	Validity of Animal Models	451
12.4.1	Face Validity	452
12.4.2	Construct Validity	452
12.4.3	Predictive Validity	452
12.5	Before the Study	459
12.5.1	Ethics	459
12.5.2	Licence Types	460

12.6	Study Design	460
12.6.1	Selecting the Species	460
12.6.2	Selecting the Model	464
12.6.3	Objectives	466
12.6.4	Selecting the Endpoint	467
12.6.5	Powering a Study	468
12.6.6	Controls	468
12.6.7	Experimental Design	469
12.7	During the Study	470
12.7.1	Animal Suppliers	470
12.7.2	Animal Housing	471
12.7.3	Animal Handling	472
12.7.4	Animal Weight and Age	473
12.7.5	Dosing	473
12.7.6	Drug Formulation	474
12.8	After the Study	474
12.8.1	Statistical Analysis	474
12.8.2	Scientific Reporting	475
12.8.3	Unexplained Data Exclusions	476
12.9	Benefits and Downfalls of Animal Research Studies	476
12.9.1	What are the Benefits?	476
12.9.2	What are the Limitations?	477
12.10	The Future	477
12.10.1	Where Animal Research is Going/New Horizons	477
12.10.2	In What Ways are People Trying to Improve the Research?	478
12.11	Summary	479
12.12	Hints and Tips	480
	List of Abbreviations	481
	References	482

## 13 Bioinformatics for Medicinal Chemistry 485

*Emma Manners, Claire O'Donovan and Maria J. Martin*

13.1	Introduction	485
13.2	From Genes to Drugs and Back Again: Past, Current and Future Perspectives on Omics Data in Drug Discovery	491
13.2.1	Drug Discovery	491
13.2.2	Drug Development	495
13.3	Resources for Understanding Targets for Medicinal Chemistry	495
13.3.1	Genes, Proteins and Functional Genomics	495
13.3.2	Reactions, Pathways and Metabolites	497
13.3.3	Drugs, Targets and Biological Effects	499
13.3.4	Systems Biology Resources and Drug Discovery	501
13.3.5	Ontologies	502
13.4	Harnessing Omics Data for Drug Discovery – The Open Targets Platform for Drug Target Identification and Prioritisation	502
13.5	Conclusions and Predictions for the Future	503

13.6 Hints and Tips	505
13.6.1 Bioinformatics Skills and Tools	505
13.6.2 Control of Gene and Protein Synthesis	505
13.6.3 Types of Genetic Variation	505
13.6.4 Targets with Limited Data	505
13.6.5 Significance in GWAS Studies	505
13.6.6 Large-scale Bioactivity Data	506
13.6.7 Accessing Data in Repositories	506
13.6.8 Bioinformatics language (Table 13.2)	506
13.7 Databases	507
Key References	510
Acknowledgements	510
References	510

## 14 Translational Science 514

*Outi Vaarala, Sammeli Liikkanen and Anu Moilanen*

14.1 Introduction	514
14.2 Target Science as a Starting Point for Drug Discovery	516
14.3 Target Identification	522
14.4 Processes and Methods of Target Validation	523
14.5 Biomarker Science	526
14.6 Digital Biomarkers	527
14.7 The Role of Data Science and Real-world Evidence in Translational Science	528
14.8 Conclusions	529
14.9 Hints and Tips	530
Key References	531
References	531

## 15 Discovery Toxicology in Lead Optimization 533

*Stefano Fontana, Simone Braggio, Mauro Corsi, Rob Riley, Chris Strock, Jenifer Bradley, Caterina Virginio and Paul Walker*

15.1 Introduction	533
15.2 <i>In Silico</i> Toxicology	533
15.2.1 <i>In Silico</i> Toxicology Tools	534
15.2.2 Databases	534
15.2.3 QSARs and Statistical Modelling	537
15.2.4 Human Knowledge-based Methods	538
15.2.5 ADME-Tox Modelling	539
15.2.6 Application of <i>In silico</i> Tools in Lead Optimization	539
15.3 Target Selectivity	540
15.3.1 The Target Panel for <i>In Vitro</i> Selectivity Evaluation	542
15.3.2 Testing Strategies	543

15.3.3 Data Interpretation	546
15.4 Cell Viability Assessment	546
15.5 <i>In Vitro</i> Liabilities	547
15.5.1 Drug-induced Liver Injury (DILI)	547
15.5.2 Cardiac Liability	548
15.5.3 Central Nervous System (CNS) Liability	554
15.6 Drug-Drug Interactions	558
15.6.1 Drug-Drug Interactions Mechanisms	558
15.6.2 CYP-driven DDI Test Systems	562
15.6.3 Drug-metabolizing Enzyme Inhibition	563
15.6.4 Pathway Identification	566
15.6.5 Drug-metabolizing Enzyme Induction	569
15.6.6 Transporter-mediated Drug Interactions	571
15.6.7 PBPK Modelling	576
15.7 Phospholipidosis	576
15.8 Phototoxicity	579
15.9 Genotoxicity	581
15.9.1 Bacterial Tests	581
15.9.2 <i>In Vitro</i> Mammalian Tests	582
15.9.3 Evaluation of Results	583
15.10 Early <i>In Vivo</i> Toxicology	583
15.10.1 Preliminary Pharmacokinetics	585
15.10.2 <i>In Vivo</i> Tox Study	585
15.10.3 Early Safety Pharmacology Evaluation	586
15.11 Hints and Tips	588
Key References	589
References	590

## 16 Toxicology and Drug Development 597

*Ilona Bebenek and Owen McMaster*

16.1 Introduction and Background	597
16.2 Toxicology Testing	598
16.2.1 Safety Pharmacology	599
16.2.2 Genetic Toxicology	600
16.2.3 General Toxicology	601
16.2.4 Developmental and Reproductive Toxicology	603
16.2.5 Carcinogenicity	604
16.2.6 Miscellaneous Studies	605
16.2.7 Toxicokinetics	605
16.3 Small Molecule Drugs vs. Biopharmaceuticals	606
16.4 Regulatory Decision Making	606
16.5 Hints and Tips	607
Disclaimer	609
Key References	609
Acknowledgements	609
References	609

## 17 Patents for Medicines

*Paul A. Brady and Andrew Cook*

611

17.1	Introduction	611
17.2	What is a Patent?	612
17.3	What Conditions Need to be Fulfilled in Order for a Patent to be Granted?	
	Patentability	615
	17.3.1 Novelty	615
	17.3.2 Inventive Step	616
	17.3.3 Industrial Applicability	619
	17.3.4 Exclusions	619
	17.3.5 Clarity and Sufficiency/Reproducibility	620
17.4	Anatomy of a Patent Specification	621
	17.4.1 The Description	621
	17.4.2 Types of Patent Claim	622
	17.4.3 Case Study (a): Typical Claims in a Pharmaceutical Patent	623
	17.4.4 Case Study (b): The Importance of Experimental Data – Inventive Step	626
	17.4.5 Case Study (c): The Importance of Experimental Data – Sufficiency	627
17.5	Ownership and Inventorship	628
17.6	The Process for Obtaining a Patent	629
	17.6.1 The National Nature of Patents	629
	17.6.2 A Typical Application Process	630
	17.6.3 Costs	631
	17.6.4 The National Phase: Examination of Patent Applications	632
	17.6.5 Strategic Aspects	633
17.7	The Patent after Grant	635
	17.7.1 Maintenance	635
	17.7.2 Extension of Patents	636
	17.7.3 Challenges to Validity	636
17.8	Use of Patents	637
	17.8.1 Infringement and Enforcement	637
	17.8.2 Defences and Exemptions to Infringement	640
	17.8.3 The Consequences of Patent Infringement	642
	17.8.4 Licensing	643
	17.8.5 The Patent Box	644
17.9	Generic Medicines and Hurdles to Generic Competition	645
	17.9.1 What is a Generic Medicine?	645
	17.9.2 Regulatory Data Exclusivity	646
	17.9.3 Technical Hurdles	647
17.10	Patents as a Source of Information	648
17.11	Summary	649
	Acknowledgements	651
	References	651

## 18 Target Validation for Medicinal Chemists 653

*Matthew Thomas and Lorna Ewart*

18.1	Introduction	653
18.2	'Hide and Seq' – Searching for Novel Targets	655
18.2.1	Genetic and Epigenetic Factors	656
18.2.2	Exploiting 'Big Data'	657
18.2.3	Finding Targets in Tissues	658
18.2.4	Starting with Quality Material	659
18.3	Phenotypic Screens – Search and Partial Validation in One System?	660
18.3.1	Techniques to Modulate Gene Expression	660
18.3.2	Screening the Secretome	661
18.4	Functional Cell Systems – Assessing 'Differential Patient Biology'	663
18.4.1	Co-culture Systems	663
18.4.2	Environmental Stimuli	664
18.4.3	Organoids	665
18.4.4	Microphysiological Systems	666
18.4.5	Cell Source	667
18.5	<i>Ex Vivo</i> Tissue Systems in Target Validation	668
18.5.1	Precision-cut Tissue Slices	668
18.5.2	Isolated Organs	669
18.6	<i>In Vivo</i> Novel Target Validation	669
18.7	Preparing for Drug Discovery	671
18.7.1	Assessing Risk in Exploratory Portfolio	672
18.7.2	Drug Discovery Transition	673
18.8	Case Study: Platelet Derived Growth Factor as a Target for Pulmonary Arterial Hypertension	674
18.9	Summary	675
18.10	Target Validation: Pro Tips	676
	Acknowledgements	678
	References	678

## 19 Lead Generation 682

*Frank Narjes, Garry Pairaudeau and Dušan Petrović*

19.1	Introduction	682
19.1.1	What Is Lead Generation and Why Do We Need It?	682
19.1.2	The Lead Generation Process	685
19.1.3	Hit Identification	686
19.1.4	Hit to Lead	687
19.2	Hit-finding Approaches	688
19.2.1	Knowledge-based Approaches	688
19.2.2	High-throughput Screening	689
19.2.3	DNA Encoded Library Screening	693

19.2.4 Focussed Screening	696
19.2.5 <i>In Silico</i> (Virtual) Screening	697
19.2.6 Fragment-based Lead Generation	701
19.2.7 Phenotypic Drug Discovery	704
19.2.8 Integrated Lead Generation Approaches	707
19.3 Hit to Lead	708
19.4 Conclusion	713
19.5 Hints and Tips	713
Key References	714
References	715

## 20 Lead Optimisation: What You Should Know! 720

*Simon E. Ward and Andrew M. Davis*

20.1 The Role of Lead Optimisation	720
20.1.1 What is Obtained from Lead Identification: Assessing the Series	721
20.1.2 Defining the Ultimate Candidate Profile	722
20.1.3 Progressing into Clinical Development – Dose Selection	726
20.1.4 The Process of Optimisation	728
20.1.5 Screening Cascade	731
20.1.6 Decision-making in the Screening Cycle	733
20.1.7 Progression Criteria	734
20.1.8 Predicted Properties	734
20.1.9 The Use of Colour to Simplify Decision-making	734
20.2 Lead Optimisation – The Practicalities	735
20.2.1 Quality of Start Point is of Paramount Importance	735
20.2.2 Starting Lead Optimisation: Identifying the Weaknesses	735
20.2.3 Formulating a Strategy for Full Lead Optimisation	736
20.2.4 Strategies to Optimise Common Parameters in Early Lead Optimisation	737
20.2.5 Drop-off in Cellular Potency and Downstream Assays	741
20.2.6 Selectivity	743
20.2.7 Solubility	745
20.2.8 Metabolism	747
20.2.9 Toxicity and Phospholipidosis	751
20.2.10 Pfizer MPO	752
20.3 The End Game: Choosing the Candidate Drug	752
20.3.1 Shortlisting	752
20.3.2 Scale-up and Safety Testing	753
20.3.3 Back-up Approaches	753
20.4 LTC4S Inhibitor LO Case Study	754
20.4.1 Pharmacological Profile of AZD9898	761
20.4.2 Human Dose Predictions	762
20.5 Hints and Tips	765
Acknowledgements	766
References	766

## **21 Pharmaceutical Properties – The Importance of Solid Form Selection** **769**

*Cheryl L. Doherty, Amy L. Robertson, Nicola Clear and Robert Docherty*

21.1	Introduction	769
21.2	Solid State Chemistry	771
21.2.1	Crystallography	771
21.2.2	Crystal Chemistry and Crystal Packing of Drug Molecules	773
21.2.3	Intermolecular Interactions, Crystal Packing Energies	773
21.2.4	Crystallisation Solubility, Supersaturation and Metastable Zone	774
21.2.5	Pharmaceutical Polymorphs and the Solid State	776
21.2.6	Polymorphism, Thermodynamic Stability and Solubility	777
21.3	Industry Practises	778
21.3.1	Salt Screening and Selection	778
21.3.2	Co-crystal Screening	780
21.3.3	Polymorph Screening	781
21.3.4	Hydrate Screening	783
21.3.5	Amorphous Forms	784
21.3.6	Manufacturability and Particle Engineering	786
21.3.7	Computational Solid Form Design	788
21.4	Integration Within the Early Clinical Phases of Development	790
21.4.1	The Changing Drug Product Design Paradigm	790
21.5	Different Requirements for Dosage Form Types	791
21.6	Integration of Enabling Formulation Strategies	792
21.7	Future Outlook	795
	References	795

## **22 The Medicinal Chemistry and Process Chemistry Interface** **800**

*William R. F. Goundry and Jeremy S. Parker*

22.1	Why is the Medicinal Chemistry–Process Chemistry Interface Important?	800
22.1.1	Strategic Differences Between Medicinal Chemistry and Process Chemistry Syntheses	800
22.1.2	What Constitutes a Good Process Chemistry Synthesis?	801
22.1.3	Early Signs of Potential Issues	802
22.2	Collaboration Opportunities at the Medicinal Chemistry–Process Chemistry Interface	803
22.2.1	Provision of Information	804
22.2.2	Sustainability	805
22.2.3	Process Safety	805
22.2.4	Route Design	806
22.2.5	Process Design	806



22.3 Emerging 21st Century Challenges	809
22.4 Concluding Remarks	810
22.5 Hints and Tips	810
Key References	810
References	811

## 23 Clinical Drug Development 812

*Maarten Kraan*

23.1 Introduction	812
23.2 Types of Clinical Trials	813
23.3 Phases of Drug Development	815
23.4 Targeted Drugs/Companion Diagnostics and Biomarkers	820
23.5 Platform of Evidence and Probability of Success	821
23.6 Basic Considerations/Principles Including Statistics	821
23.7 Target Product Profile	822
23.8 Study Protocol	822
23.9 Clinical Trial Database	823
23.10 Study Result Reporting	823
23.11 Independent Review Board (IRB)	824
23.12 Health Authorities and Ethical Considerations	824
23.13 Investigational Brochure	825
23.14 Study Teams	825
23.15 Examples of Development Programmes	825
23.16 Hints and Tips	828
Key References	828
References	829

## 24 SMN2 Splicing Modification by Small Molecules – A Blueprint to Tackle the Underlying Genetic Cause of Many Underserved Diseases 830

*Hasane Ratni, Martin Ebeling, Renata S. Scalco, Lutz Mueller and  
Alexander Stephan*

24.1 Introduction	830
24.2 Spinal Muscular Atrophy and Its Treatment Options	830
24.3 Systemic Requirement of SMN Rescue for the Treatment of SMA	834
24.4 Small Molecule SMN2 Splicing Modifiers	834
24.4.1 Discovery of Branaplam	834
24.5 Discovery of Risdiplam	836
24.6 Clinical Development of Risdiplam	839
24.7 Assessing Effects of Small Molecule Splicing Modifiers	840
24.8 Conclusions and Future Outlook	843
References	843

## **25 The Discovery of Checkpoint Kinase 1 Inhibitors: From Fragments to Clinical Candidate** **847**

*Ian Collins*

25.1	Introduction	847
25.2	CHK1 and Cancer	848
25.3	Starting Points	849
25.3.1	CHK1 Inhibitor Scaffolds and Target Profile	849
25.3.2	Collaborating to Progress CHK1 Fragment Screening	851
25.4	From Fragments to <i>In Vivo</i> Chemical Tools	852
25.4.1	Evaluating and Growing the Hit Fragments	852
25.4.2	Scaffold Morphing to Cell Active Leads	854
25.4.3	From Cell Active Chemical Tools to <i>In Vivo</i> Proof of Concept with Oral Agents	856
25.5	Clinical Candidate Discovery	859
25.5.1	Multi-parameter <i>In Vitro</i> and <i>In Vivo</i> Optimisation	859
25.5.2	<i>In Vivo</i> Pharmacology and Predictions to Human	863
25.5.3	Expanding and Defining Potential Clinical Contexts	864
25.6	Preclinical Development, Early Clinical Trials and New Clinical Contexts	866
25.7	Conclusions	868
25.8	Hints and Tips	869
	Conflict of Interest Statement	870
	Acknowledgements	870
	References	870

## **26 Medicinal Chemistry for Neglected Diseases – Malaria, Tuberculosis, Sleeping Sickness, Leishmaniasis and River Blindness** **873**

*Jeremy N. Burrows, Christopher B. Cooper, Charles Mowbray and Peter Sjö*

26.1	Introduction: Neglected Tropical Diseases and Diseases of Poverty	873
26.2	Malaria	874
26.2.1	Disease Overview	874
26.2.2	<i>Plasmodium</i> Lifecycle	875
26.2.3	Current Landscape and Strategic Focus	878
26.2.4	Antimalarial Medicinal Chemistry – Key Learnings	881
26.2.5	Portfolio – Case Studies	882
26.3	Tuberculosis	884
26.3.1	Disease Overview	884
26.3.2	<i>Mycobacterium tuberculosis</i> Lifecycle	884
26.3.3	Current Treatments, Portfolio and Gaps	886
26.3.4	Antitubercular Medicinal Chemistry – Key Learnings	890
26.3.5	Portfolio – Case Study	891

26.4	Human African Trypanosomiasis and Leishmaniasis	894
26.4.1	Disease Overview	894
26.4.2	Pathogen Lifecycles of <i>T. brucei</i> and <i>Leishmania</i> spp.	896
26.4.3	Current Treatments for HAT and Leishmaniasis	897
26.4.4	Challenges in the Discovery of Novel Treatments of HAT and Leishmaniasis	899
26.4.5	Portfolio Progress and Needs for Novel Treatments of HAT and Leishmaniasis	899
26.5	Onchocerciasis	902
26.5.1	Disease Overview, Filarial Diseases	902
26.5.2	Pathogen Lifecycle <i>Onchocerca volvulus</i>	903
26.5.3	Current Treatments of Filarial Diseases	903
26.5.4	Challenges in the Discovery of Novel Treatments of Onchocerciasis	904
26.5.5	Portfolio Progress and Need for Treatments of Filarial Diseases	904
26.6	Conclusion	906
26.7	Hints and Tips	906
	Key References	907
	Acknowledgements	907
	References	907

## 27 New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery 911

*Eric Valeur*

27.1	Introduction	911
27.2	Chemical Compositions and Architectures	912
27.2.1	Main Chemical Categories of New Modalities as Single Entities	912
27.2.2	Mixed Compositions	916
27.3	Modes-of-action of New Modalities	919
27.3.1	MOAs at the DNA Level	919
27.3.2	MOAs at the RNA Level	920
27.3.3	MOAs at the Protein Level	923
27.4	Hit Finding Strategies and Drug Design of New Modalities	926
27.4.1	Oligonucleotides	926
27.4.2	Peptides	928
27.4.3	Heterobifunctional Degraders	929
27.5	Optimisation of New Modalities	930
27.5.1	Pharmacokinetics	930
27.5.2	Safety	934
27.5.3	Delivery/Route of Administration	935
27.6	Selection of Chemical Modalities	936
27.6.1	Framework for Modality Selection	937
27.6.2	Examples of Modality Selection	939
27.6.3	Further Considerations	945

27.7 Conclusion: Clinical Progress and Perspectives	945
27.8 Hints and Tips	947
Key References	947
List of Abbreviations	948
References	948

<b>Subject Index</b>	<b>962</b>
----------------------	------------